Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration

Gebran Khneizer, Ahmad Al-Taee, Bahar Bastani *

Cited by CrossRef: 15

1- Hanna R, Tran N, Patel S, Hou J, Jhaveri K, Parikh R, Selamet U, Ghobry L, Wassef O, Barsoum M, Bijol V, Kalantar-Zadeh K, Pai A, Amin A, Kupperman B, Kurtz I. Thrombotic Microangiopathy and Acute Kidney Injury Induced After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors VEGF Blockade-Related TMA After Intravitreal Use. Front Med. 2020;7 [Crossref]

2- Phadke G, Hanna R, Ferrey A, Torres E, Singla A, Kaushal A, Kalantar-Zadeh K, Kurtz I, Jhaveri K. Review of intravitreal VEGF inhibitor toxicity and report of collapsing FSGS with TMA in a patient with age-related macular degeneration. 2021;14(10):2158 [Crossref]

3- Grechukhina K, Chebotareva N, Krasnova T. Nephrotoxicity of anti-angiogenesis drugs. Terapevticheskii arkhiv. 2020;92(6):93 [Crossref]

4- Hanna R, Barsoum M, Arman F, Selamet U, Hasnain H, Kurtz I. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. Kidney International. 2019;96(3):572 [Crossref]

5- Bevacizumab. Reactions Weekly. 2017;1657(1):80 [Crossref]

6- Hanna R, Ahdoot R, Kim M, Jhaveri K, Kalantar-Zadeh K, Kurtz I. Intravitreal vascular endothelial growth factors hypertension, proteinuria, and renal injury: a concise review. 2022;31(1):47 [Crossref]

7- Kikuchi Y, Odashima Y, Yoshikawa K, Oda T, Tanaka F, Oikawa H, Ishigaki Y, Asahi K. Renal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema. BMC Nephrol. 2022;23(1) [Crossref]

8- Yau A, Conklin E, Campion V. Secondary Membranous in the Cancer Patient. Journal of Onco-Nephrology. 2022;6(1-2):29 [Crossref]

9- Kenworthy J, Davis J, Chandra V, Clark J, Desmond M. Worsening Proteinuria Following Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema. Journal of VitreoRetinal Diseases. 2019;3(1):54 [Crossref]

10- Yang S, Su Y, Lim C, Huang J, Hsu S, Wu L, Chang Y, Hung J. Risk of dialysis in patients receiving intravitreal anti–vascular endothelial growth factor treatment: a population-based cohort study. Aging. 2022;14(12):5116 [Crossref]

11- Ke B, Huang J, Duan Z, Shen W, Wu Y, Tu W, Fang X. VEGFA promotes the occurrence of PLA2R-associated idiopathic membranous nephropathy by angiogenesis via the PI3K/AKT signalling pathway. BMC Nephrol. 2022;23(1) [Crossref]

12- Hanna R, Lopez E, Hasnain H, Selamet U, Wilson J, Youssef P, Akladeous N, Bunnapradist S, Gorin M. Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. 2019;12(1):92 [Crossref]

13- Gan G, Michel M, Max A, Sujet‐Perone N, Zevering Y, Vermion J, Zaidi M, Savenkoff B, Perone J. Membranoproliferative glomerulonephritis after intravitreal vascular growth factor inhibitor injections: A case report and review of the literature. Brit J Clinical Pharma. 2023;89(1):401 [Crossref]

14- Shye M, Hanna R, Patel S, Tram-Tran N, Hou J, Mccannel C, Khalid M, Hanna M, Abdelnour L, Kurtz I. Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy. 2020;13(6):969 [Crossref]

15- Grechukhina K, Chebotareva N, Zhukova L, Krasnova T. Clinical and laboratory signs and risk factors for nephrotoxicity, associated with antiangiogenic drugs. Terapevticheskii arkhiv. 2021;93(6):661 [Crossref]